Antagonism of the GR by mifepristone (RU486), pharmacologically classified as both a progesterone and glucocorticoid antagonist [9], has been shown to ameliorate metabolic parameters in rodent model of type 2 diabetes (T2D) [10]. The gene discussed is NR3C1; the disease is type 2 diabetes mellitus.